Effects of adalimumab therapy on musculoskeletal manifestations and health-related quality of life in patients with active psoriatic arthritis

详细信息    查看全文

• 作者：Shigeyoshi Tsuji (1)
  Mari Higashiyama (2)
  Masahiro Inaoka (3)
  Tetsuya Tomita (4)
  Akinori Yokomi (2)
  Ayako Satoh (2)
  Ayuko Hirano (2)
  Misa Hayashi (2)
  Maki Tsuji (2)
  Yasuo Kunugiza (4)
  Masayuki Hamada (1)
  Hideki Yoshikawa (4)
  
• 关键词：Adalimumab ; Biologics ; Methotrexate ; Psoriasis ; Psoriatic arthritis
• 刊名：Modern Rheumatology
• 出版年：2013
• 出版时间：May 2013
• 年：2013
• 卷：23
• 期：3
• 页码：529-537
• 全文大小：523KB
• 参考文献：1. Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risks of death. Arthritis Rheum. 1997;40:1868-2. CrossRef
  2. Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 2003;42:1460-. CrossRef
  3. Lie E, van der Heijde D, Uhlig T, Heiberg MS, Koldingsnes W, R?devand E, et al. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69:671-. 6/ard.2009.113308">CrossRef
  4. Willkens RF, Williams HJ, Ward JR, Egger MJ, Reading JC, Clements PJ, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum. 1984;27:376-1. CrossRef
  5. Murata N. Psoriatic arthritis update (in Japanese). Rheumatology (Tokyo). 2007;38:446-2.
  6. Ishikawa H, Kanamono T. Current state of treatment of psoriatic arthritis in this hospital (in Japanese). J Chubu Rheum Assoc. 2009;40:18-.
  7. Tsuji S, Higashiyama M, Yokomi A, Satoh A, Hirano A, Hayashi M, et al. Efficacy and safety of MTX in patients with psoriatic arthritis (in Japanese). In: The 25th Annual Meeting of the Japanese Society for Psoriasis Research. 3- Sept 2010; Yamaguchi, Japan; p. 221
  8. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385-0. 6/S0140-6736(00)02530-7">CrossRef
  9. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005;52:1227-6. 67">CrossRef
  10. Gladman DD, Mease PJ, Ritchlin CT, Choy EHS, Sharp JT, Ory PA, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 2007;56:476-8. CrossRef
  11. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665-3. CrossRef
  12. Moll JMH, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3:55-8. 6/0049-0172(73)90035-8">CrossRef
  13. Ohtsuki M, Terui T, Ozawa A, Morita A, Sano S, Takahashi H, et al. The guideline and safety manual for use of anti-TNFα agents in psoriasis (in Japanese). Jpn J Dermatol. 2010;120:163-1.
  14. Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: eULARA/ACR collaborative recommendations. Ann Rheum Dis. 2008;67:1360-. 6/ard.2008.091454">CrossRef
  15. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. Arthritis Rheum. 1996;39:2013-0. CrossRef
  16. Oribe M. In: Abe C, Kondo M, Matsubara T, Yamasaki K, editors. The manual of rheumatoid arthritis therapy with biologics. Tokyo: Nihon Igakukan; 2010. p. 116-.
  17. Ziebland S, Fitzpatrick R, Jenkinson C, Mowat A, Mowat A. Comparison of two approaches to measuring change in health status in rheumatoid arthritis: the Health Assessment Questionannaire (HAQ) and modified HAQ. Ann Rheum Dis. 1992;51:1202-. 6/ard.51.11.1202">CrossRef
  18. Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of Spondyloarthritis International Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68:ii1-4.
  19. Fukuhara S, Suzukamo Y. Manual of SF-36v2 (in Japanese). Kyoto: Institute for Health Outcomes and Process Evaluation Research; 2004.
  20. Gladman DD, Mease PJ, Cifaldi MA, Perdok RJ, Sasso E, Medich J. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the adalimumab effectiveness in psoriatic arthritis trial. Ann Rheum Dis. 2007;66:163-. 6/ard.2006.057901">CrossRef
  21. Ash Z, Gaujoux-Viala C, Gossec L, Hensor EM, Fitzgerald O, Winthrop K, et al. Systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2012;71(3):319-6. 6/ard.2011.150995">CrossRef
  22. Scarpa R, Peluso R, Atteno M, Manguso F, Spano A, Iervolino S, et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate. Clin Rheumatol. 2008;27(7):823-. 67-007-0787-7">CrossRef
  23. Willkens RF, Williams HJ, Ward JR, Egger MJ, Reading JC, Clements PJ. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum. 1984;27(4):376-1. CrossRef
  24. Salvarani C, Macchioni P, Olivieri I, Marchesoni A, Cutolo M, Ferraccioli G. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol. 2001 Oct;28(10):2274-2.
  25. Tsuji S, Tomita T, Inaoka M, Higashiyama M. Case report: psoriatic erythroderma with bilateral osseous bridge across the acetabulum. Clin Orthop Relat Res. 2010;468(4):1173-. CrossRef
  26. Heydendael VM, Spuls PI, Opmeer BC, de Borgie CA, Reitsma JB, Goldschmidt WF. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med. 2003;349(7):658-5. 6/NEJMoa021359">CrossRef
  27. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section?6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65:137-4. 6/j.jaad.2010.11.055">CrossRef
  28. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EHS, et al. Adalimumab for the treatment of patients with moderately to severely active psoriasis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279-9. 6">CrossRef
  29. Suzukamo Y, Fukuhara S, Green J, Kosinski M, Gandek B, Ware JE. Validation testing of a three-component model of Short Form-36 scores. J Clin Epidemiol. 2011;64:301-. 6/j.jclinepi.2010.04.017">CrossRef
  
• 作者单位：Shigeyoshi Tsuji (1)
  Mari Higashiyama (2)
  Masahiro Inaoka (3)
  Tetsuya Tomita (4)
  Akinori Yokomi (2)
  Ayako Satoh (2)
  Ayuko Hirano (2)
  Misa Hayashi (2)
  Maki Tsuji (2)
  Yasuo Kunugiza (4)
  Masayuki Hamada (1)
  Hideki Yoshikawa (4)
  
  1. Department of Orthopaedic Surgery, Hoshigaoka Koseinenkin Hospital, 4-8-1 Hoshigaoka, Hirakata, Osaka, 573-8511, Japan
  2. Department of Dermatology, Nissay Hospital, Osaka, Japan
  3. Department of Orthopaedic Surgery, Nissay Hospital, Osaka, Japan
  4. Department of Orthopaedics, Osaka University Graduate School of Medicine, Suita, Japan
  
• ISSN：1439-7609

文摘

Objectives Adalimumab, a fully human anti-tumor necrosis factor monoclonal antibody, was retrospectively evaluated for its effect on musculoskeletal manifestations and health-related quality of life in patients with psoriatic arthritis (PsA) during daily clinical practice. Methods Patients who initiated adalimumab therapy after March 2010 were followed for at least 24?weeks with the clinical outcome measures. Eleven patients, all men with a mean age of 45.4?years, had mean psoriasis durations of 16.2 and 8.4 years at baseline. Results After 24?weeks, 72.7, 63.6, and 45.5?% of the patients met the ACR 20, 50, and 70 response criteria, respectively, while 81.8?% achieved the PsA response criteria. Disease Activity Score using the 28-joint count and CRP declined from 3.2?±?1.2 at baseline to 1.3?±?0.4 at week 24 (P?<?0.01). The Bath Ankylosing Spondylitis Disease Activity Index and Bath Ankylosing Spondylitis Functional Index scores also decreased significantly (both P values were <0.01). After 24?weeks, three out of eight dimensions of the Medical Outcomes Study 36-Item Short Form Health Survey and Physical Component Summary were significantly improved (all P values were <0.05). Conclusions Adalimumab exerted its effect as early as week 4, and it was sustained until the end of the 24-week observation period in the PsA patients.